Prescription Drug Monitoring Program Mandates and Opioids Dispensed Following Emergency Department Encounters for Patients With Sickle Cell Disease or Cancer With Bone Metastasis
Open Access
- 20 July 2021
- journal article
- letter
- Published by American Medical Association (AMA) in Jama-Journal Of The American Medical Association
- Vol. 326 (3), 274-276
- https://doi.org/10.1001/jama.2021.10161
Abstract
Patients with sickle cell disease (SCD) or cancer with bone metastasis often present to the emergency department (ED) for treatment of severe pain,1,2 and opioid analgesics remain first-line therapies for acute pain in the ED or after discharge.3 Policies aimed at improving the safety of opioid prescribing, such as state legislative mandates that prescribers register with or use prescription drug monitoring programs (PDMPs),4 may inadvertently limit access to opioids for these patients.5 We examined the association between implementation of PDMP mandates and changes in opioids dispensed to these patients following ED encounters.Keywords
This publication has 5 references indexed in Scilit:
- American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic painBlood Advances, 2020
- Prescription Drug Monitoring Program Mandates: Impact On Opioid Prescribing And Related Hospital UseHealth Affairs, 2019
- No Shortcuts to Safer Opioid PrescribingThe New England Journal of Medicine, 2019
- Why Do Patients With Cancer Visit Emergency Departments? Results of a 2008 Population Study in North CarolinaJournal of Clinical Oncology, 2011
- The burden of emergency department use for sickle‐cell disease: An analysis of the national emergency department sample databaseAmerican Journal of Hematology, 2010